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New Drug: Prevacid I.V. (Lansoprazole) Injection 
Lead author: Joseph A. Woelfel, Ph.D. FASCP, R.Ph., Assistant Editor 
*Updated information on Protonix I.V. may be found at the end of this document.* 
 
What It Is 
Prevacid I.V. (lansoprazole) is an intravenous 
proton pump inhibitor.1 
 
Indications 
When patients are unable to take oral 
formulations of lansoprazole, Prevacid I.V. is a 
short–term alternative for all grades of erosive 
esophagitis.  It is intended for administration up to 
seven days.  Once patients are able to take oral 
medications, they should be switched to oral 
Prevacid for a total of six to eight weeks.1 
 
How Supplied 
Prevacid I.V. is available as a single-dose vial 
containing 30 mg of lansoprazole powder.  The 
single-dose vial is supplied in a pack containing a 
1.2 micron in-line filter which is required for its 
administration.  It is supplied in a tray of ten 
packs.1 
It should be stored at room temperature 25oC 
(77oF) [range 15oC to 30oC or 59oF to 86oF] and 
protected from light.1 
 
Dosage 
The recommended adult dosage for Prevacid 
I.V. for use in erosive esophagitis is 30 mg daily 
administered by intravenous infusion over 30 
minutes for up to seven days.  It is intended only 
for patients unable to take oral therapy.  Oral 
therapy should be started as soon as possible.1 
No dosage adjustment is needed in renal 
impairment or in the elderly.  Patients with severe 
hepatic disease may need dosage reduction.1 
 
Admixture Preparation and Administration 
Reconstitute each 30 mg vial with 5 mL of 
Sterile Water for Injection, USP.  After gentle 
mixture, the resultant solution can be kept at room 
temperature for one hour prior to further dilution.1   
The reconstituted solution must then be further 
diluted in 50 mL of either 0.9% Sodium Chloride 
Injection USP, 5% Dextrose Injection USP, or 
Lactated Ringer’s Injection, USP prior to 
administration.1   
Solutions in 5% Dextrose Injection, USP must 
be used within 12 hours at room temperature, 
whereas those in 0.9% Sodium Chloride Injection 
USP or Lactated Ringer’s Injection, USP can be 
used in 24 hours.  Refrigeration is not required.1 
The resulting infusion must be administered 
using the in-line filter provided over a 30 minute 
period.  The filter must be used to remove any 
precipitate formed when the reconstituted product 
is mixed with intravenous solutions.  Filtration 
does not alter the amount of lansoprazole 
available to the patient.1   
 
Manufacturer 
TAP Pharmaceuticals Inc.  





Erosive esophagitis is a serious chronic form 
of gastroesophageal reflux disease (GERD).  It is 
characterized by symptoms of heartburn, acid 
regurgitation, and abdominal discomfort.  If 
untreated it can cause esophageal mucosal damage 
and lead to complications such as stricture, 
hemorrhage, and esophageal cancer.2,3  Acid 
suppressive therapy is the primary therapy for 
GERD.2  Evidence-based medicine supports the 
use of proton pump inhibitors over H2-blockers 
for severe cases of GERD [Evidence level C, 
consensus].2 
Prevacid I.V. (lansoprazole) is the second 
intravenous proton pump inhibitor to be approved 
in the U.S.  It is not yet approved in Canada. 
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Protonix I.V. (pantoprazole) was approved in 
March 2001 as an alternative to oral therapy for 
short-term use in gastroesophageal reflux disease 
associated with a history of erosive esophagitis.  
The dosage is 40 mg once daily via intravenous 
infusion.  It was later approved for use in 
Zollinger-Ellison syndrome where oral therapy 
was not possible.  An 80 mg adult dose every 12 
hours is recommended for this indication.  In 
Canada, it is also approved for treatment of non-
steroidal anti-inflammatory drug-induced ulcers.  
A 15 minute infusion or a recently approved two 
minute infusion is needed.4 
Both of these proton pump inhibitors have 
similar adverse effects, drug interactions, 
contraindications, and precautions.  They are both 
listed as Pregnancy Category B.  
Protonix I.V. is supplied in 40 mg vials that 
must be refrigerated at 2 oC to 8oC (36 oF to 46oF).  
Once prepared for intravenous administration, 
solutions are stable at room temperature for 22 
hours.4 
The average wholesale cost for Prevacid I.V. is 
listed as $26.83 per 30 mg vial whereas Protonix 
I.V. costs $29.28 per 40 mg vial.5  
Both Prevacid I.V. and Protonix I.V. are 
intended for short term therapy in patients who are 
unable to take oral proton pump inhibitors.  
Protonix I.V. has the additional approved 
indication for use in Zollinger-Ellison Syndrome.  
Protonix I.V. requires refrigeration whereas 
Prevacid I.V. does not.  Protonix I.V. has the 
advantage of a two minute infusion time and does 
not require an in-line filter.  In-line filtration was 
required for the older formulations of Protonix 
I.V.  Recently reformulated versions do not.  
Prevacid I.V. requires a 30 minute infusion period 
and the use of an in-line filter.1,4 
There are no comparative clinical studies of 
the intravenous efficacy of these two proton pump 
inhibitors.   
Formulary choices will probably be driven by 
group purchasing organization contract prices 
because of the similarities of these intravenous 
proton pump inhibitors. 
*On October 28, 2004, the FDA approved a 
supplemental new drug application submitted by 
Wyeth Pharmaceuticals for room temperature 
storage of Protonix I.V.6  Wyeth will begin 
shipment of room temperature storage Protonix 
I.V. in the first quarter of 2005.  This change 
results from formulation changes.  Current 
product on shelves and in distribution must still be 
refrigerated.   
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
 
Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based 
clinical review article.  Am Fam Physician 2002;65:251-8. 
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